We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

145 hedge funds and large institutions have $322M invested in Cymabay Therapeutics in 2020 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

21% more funds holding

Funds holding: 120 → 145 (+25)

14% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 36

23% less capital invested

Capital invested by funds: $416M → $322M (-$94.1M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

52% less call options, than puts

Call options by funds: $1.9M | Put options by funds: $3.98M

Holders
145
Holders Change
+25
Holders Change %
+20.83%
% of All Funds
2.57%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
46
Increased
41
Reduced
36
Closed
21
Calls
$1.9M
Puts
$3.98M
Net Calls
-$2.08M
Net Calls Change
-$4.62M

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$6.59M
2
Goldman Sachs
Goldman Sachs
New York
+$6.44M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$6.11M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.29M
5
BlackRock
BlackRock
New York
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$12.6M
2
RG
Redmile Group
California
-$12.4M
3
VC
Vivo Capital
California
-$11.4M
4
Norges Bank
Norges Bank
Norway
-$7.67M
5
VOYA Investment Management
VOYA Investment Management
Georgia
-$4.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
RJFSA
151
Raymond James Financial Services Advisors
Florida
– -$323K -44,598 Closed
CCIA
152
Campbell & Co Investment Adviser
Maryland
– -$245K -33,800 Closed
PP
153
PDT Partners
New York
– -$194K -26,799 Closed
BCM
154
Bayesian Capital Management
New York
– -$162K -22,400 Closed
AI
155
Atom Investors
Texas
– -$155K -21,477 Closed
ECM
156
ExodusPoint Capital Management
New York
– -$145K -19,971 Closed
MAM
157
Meeder Asset Management
Ohio
– -$77K -10,770 Closed
Simplex Trading
158
Simplex Trading
Illinois
– -$28.6K -3,780 -53%
Osaic Holdings
159
Osaic Holdings
Arizona
– -$14K -2,000 Closed
CG
160
Cutler Group
California
– -$4K -600 Closed
GWS
161
Glassman Wealth Services
Virginia
– -$4K -535 Closed
GT
162
Glenmede Trust
Pennsylvania
– -$1K -273 Closed
FFA
163
Founders Financial Alliance
North Carolina
– -$1K -200 Closed
ASN
164
Advisory Services Network
Georgia
– -$303 -40 Closed
CWC
165
Carolinas Wealth Consulting
North Carolina
– +$76 +10 New
EI
166
Ellevest Inc
New York
– +$250 +33 New
3 4 5 6
7

CBAY Hedge Fund Activity: Q4 2020 in Review

145 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2020, worth a combined $322M — down 23% from $416M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new CBAY positions and 21 closed out — a net gain of 25 holders — while 41 added to existing stakes and 36 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $6.59M. The largest seller was Invesco, cutting an estimated $12.6M.

  • 145 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2020, up from 120 in Q3 2020.
  • Funds reported $322M of Cymabay Therapeutics stock for Q4 2020, down 23% quarter-over-quarter.
  • 46 funds opened new Cymabay Therapeutics positions in Q4 2020 and 21 closed out, a net change of +25 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2020 was Two Sigma Investments, an estimated $6.59M added.
  • The largest Cymabay Therapeutics seller in Q4 2020 was Invesco, an estimated $12.6M sold.

Based on aggregated 13F filings for Q4 2020.